Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

TRD is a severe type of major depressive disorder in which patients ... that patients will be able use the ketamine-derived nasal spray, which is marketed under the brand name Spravato, without ...

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...

offering both NeuroStar Advanced Therapy (transcranial magnetic stimulation or “TMS”) and Spravato® (esketamine nasal spray) for the treatment of major depressive disorder (“MDD”) and other mental ...

Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in ...

Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...

(A ketamine-derived drug called esketamine is approved for some people as part of treatment-resistant major depressive disorder ... usually get the esketamine nasal spray twice a week for one ...

The largest life sciences association in the state recognized those driving discovery during its 32nd annual dinner meeting ...

For people with treatment-resistant depression, your doctor may suggest esketamine-intranasal spray along with an oral antidepressant to help ease symptoms. If you have major depressive disorder ...